BBSRC and DFID co-funding has enabled a collaboration between UK researchers at The Pirbright Institute, formerly the Institute for Animal Health, and the University of Glasgow, with counterparts in South Africa and the largest vaccine manufacturer in South Asia, to improve vaccines against foot-and-mouth disease (FMD).
|£100M+||Level of investment currently underway at IAH Pirbright site|
|7||Number of recognised serotypes of FMD|
|£13M||Funding for the CIDLID programme|
Research led by Professor Satya Parida, Head of the Vaccine Differentiation Group at IAH, aims to improve vaccines against FMD in east Africa where the disease has a major impact on the livelihoods of rural subsistence farmers.
The researchers will identify novel adjuvants to boost the effectiveness of FMD vaccines. They will also identify the most suitable virus strains for use in an FMD vaccine in east Africa and create a model to allow developing countries to test vaccines in laboratories rather than relying on animal tests in expensive high-containment facilities. The project builds on IAH’s substantial expertise in FMD research, which includes being the FMD World Reference Laboratory for the UN’s Food and Agriculture Organisation.
The projects is part of the Combating Infectious Diseases of Livestock for International Development (CIDLID) initiative; a programme co-funded by BBSRC and DFID with a contribution from the Scottish Government.
Read the full impact-evidence-report (PDF 153KB) .